NCT00045812View on ClinicalTrials.gov

SCH-58235 (Ezetimibe) to Treat Homozygous Sitosterolemia

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

March 31, 2001

Study Completion Date

April 30, 2004

Conditions
Lipoidosis
Interventions
DRUG

SCH-58235

Trial Locations (1)

20892

National Heart, Lung and Blood Institute (NHLBI), Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT00045812 - SCH-58235 (Ezetimibe) to Treat Homozygous Sitosterolemia | Biotech Hunter | Biotech Hunter